Funding Support and Author Disclosures Dr Galli has received consulting fees from Genomadix; is the principal investigator of the following active grant: Sapienza University of Rome (Grant protocol n. RG1241910F5A1A50); and is an associate editor at European Heart Journal. Dr Federici has received consulting fees or honoraria from Amgen, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Merck Sharp and Dohme, Novartis, Novo Nordisk, and Sanofi. Dr Mehran has received institutional research funding from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Amgen, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi-Sankyo, Element Science, Faraday, Humacyte, Idorsia Pharmaceuticals, Janssen, Medtronic, Novartis, OrbusNeich, PhaseBio, Philips, Pi-Cardia, RenalPro, Shockwave, Vivasure, and Zoll; has received personal fees from Cine-Med Research and WebMD; has equity <1% in Applied Therapeutics, Elixir Medical, Stel, and ControlRad (spouse); serves on scientific advisory board for the American Medical Association, American College of Cardiology (board of trustees member), Society for Cardiovascular Angiography and Interventions (Women in Innovations committee member), and an associate editor at JAMA; and is unpaid faculty of the Cardiovascular Research Foundation. Dr Angiolillo has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, CSL Behring, Daiichi-Sankyo, Eli Lilly, Faraday, Haemonetics, Janssen, Merck, Novartis, Novo Nordisk, PhaseBio, PLx Pharma, Pfizer, and Sanofi; and his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Faraday, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, and the Scott R. MacKenzie Foundation. Dr Sciarretta has received honoraria for speeches and/or advisory board participation from Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PubMed
